[Value of malarone in therapy of malaria tropica].

Abstract

BACKGROUND:

A widespread resistance of falciparum malaria to common antimalaria drugs is observed during the last years. Long-distance travel to high-risk destinations of falciparum malaria will contribute to increased exposition of travelers to highly resistant parasites.

PHARMACOLOGY:

Malarone (GlaxoSmithKline) is a fixed combination of atovaquone and proguanil licensed for prophylaxis and treatment of falciparum malaria. Both atovaquone and proguanil demonstrate synergistic activity against liver and blood schizonts. Malarone is well tolerated with a low rate of side effects. Malarone has an excellent efficacy profile in nonimmune subjects.

CONCLUSIONS:

Malarone appears to be a valuable alternative malaria prophylaxis in case of intolerance of other antimalaria drugs. Atovaquone/proguanil is effective in treating acute uncomplicated malaria caused by multiresistant strains of Plasmodium falciparum.

• Authors: Tom Ziegler, Anja Schau, Christina Winkler
• Journal: Medizinische Klinik (Munich, Germany : 1983) (Med Klin (Munich)) Vol. 97 Issue 8 Pg. 455-8 (Aug 15 2002) ISSN: 0723-5003 [Print] Germany
• Vernacular Title: Stellenwert von Malarone in der Therapie der Malaria tropica.
• PMID: 12229244 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antimalarials
• Drug Combinations
• Naphthoquinones
• atovaquone, proguanil drug combination
• Proguanil
• Atovaquone

Topics

• Animals
• Antimalarials (adverse effects, therapeutic use)
• Atovaquone
• Drug Combinations
• Drug Resistance
• Humans
• Malaria, Falciparum (drug therapy, parasitology)
• Naphthoquinones (adverse effects, therapeutic use)
• Plasmodium falciparum (drug effects)
• Proguanil (adverse effects, therapeutic use)
• Randomized Controlled Trials as Topic